Article Details
Retrieved on: 2024-10-07 16:38:54
Tags for this article:
Click the tags to see associated articles and topics
Summary
The article discusses a securities class action against Moderna due to misleading statements about the efficacy of their RSV vaccine, mRNA-1345, affecting stock values. This relates to the tags on vaccines, medical research, and Moderna, particularly under the broader context of mRNA technology used in COVID-19 vaccines.
Article found on: markets.businessinsider.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here